Gastroprotective Agent Utilization and Compliance in Patients > 60 Years Taking Low-dose Aspirin in France

This study has been withdrawn prior to enrollment.
Information provided by:
AstraZeneca Identifier:
First received: November 9, 2010
Last updated: June 6, 2011
Last verified: June 2011

The purpose of this study is to assess in general population low-dose aspirin and gastroprotective agent compliance and reasons for bad compliance

Self-administered Questionnaire to Patients

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Gastroprotective Agent Utilization and Compliance in Patients > 60 Years Taking Low-dose Aspirin in France

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • low-dose aspirin and gastroprotective treatment compliance (Girerd questionnaire: a 6-item self-administered and validated questionnaire to evaluate adherence to treatments) [ Time Frame: One month ] [ Designated as safety issue: No ]

Estimated Enrollment: 7300
Study Start Date: June 2011
Estimated Study Completion Date: July 2011
Estimated Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)


Ages Eligible for Study:   60 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Community sample


Inclusion Criteria:

  • French people > 60 years old, part of Kantar Health Access Sant� panel

Exclusion Criteria: -

  Contacts and Locations
Please refer to this study by its identifier: NCT01238809

Sponsors and Collaborators
Principal Investigator: Mrs Genevieve BONNELYE KantarHealth - France
  More Information

No publications provided

Responsible Party: MC MD, AstraZeneca Identifier: NCT01238809     History of Changes
Other Study ID Numbers: NIS-CFR-DUM-2010/1
Study First Received: November 9, 2010
Last Updated: June 6, 2011
Health Authority: France: French Data Protection Authority

Keywords provided by AstraZeneca:
France processed this record on April 23, 2014